{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:25:32Z","timestamp":1789770332137,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jpba.2017.02.002","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T01:45:28Z","timestamp":1486172728000},"page":"223-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["UPLC\u2013MS\/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma"],"prefix":"10.1016","volume":"138","author":[{"given":"Marco","family":"Simiele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ariaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"De Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Favata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Carcieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2017.02.002_bib0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ijos.2013.76","article-title":"Thirty years of the human immunodeficiency virus epidemic and beyond","volume":"5","author":"Younai","year":"2013","journal-title":"Int. J. Oral Sci."},{"key":"10.1016\/j.jpba.2017.02.002_bib0010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11904-014-0207-y","article-title":"Understanding HIV compartments and reservoirs","volume":"11","author":"Svicher","year":"2014","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.jpba.2017.02.002_bib0015","first-page":"12","article-title":"A review of rilpivirine and elvitegravir resistance features and implications for treatment sequencing","volume":"24","author":"Bourgeois","year":"2012","journal-title":"HIV Clin."},{"key":"10.1016\/j.jpba.2017.02.002_bib0020","first-page":"35","article-title":"Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings","volume":"3","author":"Ford","year":"2011","journal-title":"HIV AIDS (Auckl)"},{"key":"10.1016\/j.jpba.2017.02.002_bib0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e31824d006e","article-title":"Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials","volume":"60","author":"Cohen","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jpba.2017.02.002_bib0030","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2017.02.002_bib0035","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2017.02.002_bib0040","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s40265-014-0256-y","article-title":"Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.jpba.2017.02.002_bib0045","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00002030-200203001-00002","article-title":"Therapeutic drug monitoring in HIV infection: current status and future directions","volume":"16","author":"Back","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jpba.2017.02.002_bib0050","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/14740331003767395","article-title":"Therapeutic drug monitoring in highly active antiretroviral therapy","volume":"9","author":"Liu","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jpba.2017.02.002_bib0055","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jms.3200","article-title":"A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients","volume":"48","author":"Aouri","year":"2013","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2017.02.002_bib0060","first-page":"225","article-title":"A sensitive HPLC-MS\/MS method for the determination of dolutegravir in human plasma","volume":"945\u2013946","author":"Bennetto-Hood","year":"2013","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.02.002_bib0065","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/bmc.2765","article-title":"Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma","volume":"27","author":"Burugula","year":"2012","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2017.02.002_bib0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpba.2013.08.002","article-title":"Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS\/MS technology","volume":"86","author":"Djerada","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.02.002_bib0075","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jchromb.2010.03.036","article-title":"Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS\/MS) assay for the simultaneous determination of existing and new antiretroviral compounds","volume":"878","author":"Else","year":"2010","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.02.002_bib0080","article-title":"Reliable LC-MS\/MS assay for the estimation of rilpivirine in human plasma: application to a bioequivalence study and incurred sample reanalysis","author":"Gupta","year":"2014","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.jpba.2017.02.002_bib0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2152\/jmi.60.35","article-title":"Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations","volume":"60","author":"Shibata","year":"2013","journal-title":"J. Med. Invest."},{"key":"10.1016\/j.jpba.2017.02.002_bib0090","series-title":"Guideline on Bioanalytical Method Validation","author":"EMA","year":"2011"},{"key":"10.1016\/j.jpba.2017.02.002_bib0095","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"FDA","year":"2013"},{"key":"10.1016\/j.jpba.2017.02.002_bib0100","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/FTD.0b013e318189596d","article-title":"An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients","volume":"30","author":"D'Avolio","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2017.02.002_bib0105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jchromb.2006.10.030","article-title":"A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method","volume":"848","author":"D'Avolio","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.02.002_bib0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpba.2013.02.025","article-title":"A UPLC-MS\/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir","volume":"78\u201379","author":"D'Avolio","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.02.002_bib0115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jpba.2015.08.004","article-title":"UPLC-MS\/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells","volume":"115","author":"De Nicol\u00f2","year":"2015","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516314534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516314534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T12:25:32Z","timestamp":1536063932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516314534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":23,"alternative-id":["S0731708516314534"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.02.002","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UPLC\u2013MS\/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}